Literature DB >> 8170465

On the expression of the p53 protein in human cancer.

D P Lane1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8170465     DOI： 10.1007/bf00987319

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN： 0301-4851            Impact factor:   2.316


× No keyword cloud information.
  33 in total

1.  The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

Authors:  M Scheffner; K Münger; J C Byrne; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

2.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

3.  Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins.

Authors:  C C Kao; P R Yew; A J Berk
Journal:  Virology       Date:  1990-12       Impact factor: 3.616

4.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

5.  p53 expression and prognosis in gastric carcinoma.

Authors:  H M Martin; M I Filipe; R W Morris; D P Lane; F Silvestre
Journal:  Int J Cancer       Date:  1992-04-01       Impact factor: 7.396

6.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

7.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

Authors:  J Isola; T Visakorpi; K Holli; O P Kallioniemi
Journal:  J Natl Cancer Inst       Date:  1992-07-15       Impact factor: 13.506

8.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

Authors:  C J Kemp; L A Donehower; A Bradley; A Balmain
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

10.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506
View more
  9 in total

Review 1.  Molecular genetic analysis in the pathologic evaluation of solid tumors: theory and practice.

Authors:  D W Visscher; F H Sarkar; J D Crissman
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

2.  Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population.

Authors:  Meenakshi Umar; Rohit Upadhyay; Rohini Khurana; Shaleen Kumar; Uday Chand Ghoshal; Balraj Mittal
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

3.  Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.

Authors:  Liselotte P van Hest; Mariëlle W G Ruijs; Anja Wagner; Conny A van der Meer; Senno Verhoef; Laura J van't Veer; Hanne Meijers-Heijboer
Journal:  Fam Cancer       Date:  2007-02-23       Impact factor: 2.375

4.  Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.

Authors:  L G Kindblom; M Ahldén; J M Meis-Kindblom; G Stenman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  A simple p53 functional assay for screening cell lines, blood, and tumors.

Authors:  J M Flaman; T Frebourg; V Moreau; F Charbonnier; C Martin; P Chappuis; A P Sappino; I M Limacher; L Bron; J Benhattar
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

6.  p53 protein expression in nephroblastomas: a predictor of poor prognosis.

Authors:  D Govender; P Harilal; G P Hadley; R Chetty
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer.

Authors:  Vahinipriya Manoharan; Eric Hamilton Karunanayake; Kamani Hemamala Tennekoon; Sumadee De Silva; Kanishka De Silva; Preethika Angunawela; John Lunec
Journal:  Mol Med Rep       Date:  2019-02-11       Impact factor: 2.952

Review 8.  The consequence of oncomorphic TP53 mutations in ovarian cancer.

Authors:  Pavla Brachova; Kristina W Thiel; Kimberly K Leslie
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

9.  Evaluating the association between p53 codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysis.

Authors:  Mohammed A A Alqumber; Naseem Akhter; Shafiul Haque; Aditya K Panda; Raju K Mandal
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.